Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ganciclovir + mesalazine + papaverine
- Development stage
- Preclinical
- Modality
- Small Molecules
- Administration
- Intravenous, Oral, Rectal
01
Overview
A combination therapy used for treating severe ulcerative colitis complicated by cytomegalovirus colitis and microcirculatory disturbance. This specific combination was documented in a case study where ganciclovir was used as an antiviral agent for CMV colitis, mesalazine as an anti-inflammatory for ulcerative colitis, and papaverine was added as a vasodilator to address microcirculatory disturbance. The addition of papaverine resulted in dramatic improvement of symptoms that had been resistant to the initial treatments.
02
Targets
Beyond the preview
Go deeper on ganciclovir + mesalazine + papaverine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ganciclovir + mesalazine + papaverine.